Physician profile
Dennis E Dilley
NPI 1720029218
$6,312.84
in general payments reported to CMS, 2019-2025
39 companies · $799 in 2025
The $799 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,138 · 2020: $820 · 2021: $1,003 · 2022: $784 · 2023: $937 · 2024: $831 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,567.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $886.75 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $836.30 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Csl Behring | $687.30 | 2019-2024 | Haegarda |
| Regeneron Healthcare Solutions, INC. | $640.39 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $445.12 | 2020-2025 | Cuvitru, Eohilia, Takhzyro |
| Pfizer INC. | $264.38 | 2019-2023 | |
| Genentech USA, INC. | $249.92 | 2019-2024 | Xolair |
| Octapharma USA, INC. | $229.00 | 2019-2025 | Cutaquig |
| Optinose US, INC. | $222.02 | 2019-2025 | |
| Kaleo, INC. | $216.23 | 2019-2024 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $175.97 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $137.65 | 2019-2025 | |
| Greer Laboratories, INC. | $129.54 | 2019-2025 | Palforzia, Oralair |
| Aytu Biopharma, INC. | $110.09 | 2020-2021 | |
| Grifols USA, LLC | $106.94 | 2020-2025 | Xembify |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $101.82 | 2019-2020 | |
| Genzyme Corporation | $98.72 | 2019-2024 | |
| Biocryst US Sales Co., LLC | $72.77 | 2021-2024 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.79 | 2022-2023 | Spiriva Respimat, Stiolto Respimat |
| Jubilant Hollisterstier LLC | $65.17 | 2019 | |
| Incyte Corporation | $64.96 | 2021-2022 | |
| Adma Biomanufacturing LLC | $53.91 | 2021-2022 | |
| Alk-Abello, INC | $52.23 | 2021-2025 | Ragwitek, Odactra, Grastek |
| Amgen INC. | $48.49 | 2021-2023 | Tezspire |
| Lilly USA, LLC | $45.67 | 2024-2025 | Ebglyss, Taltz |
| Horizon Therapeutics Plc | $42.42 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $40.54 | 2025 | Neffy |
| Blueprint Medicines Corporation | $33.94 | 2023-2024 | Ayvakit |
| Organon LLC | $25.84 | 2025 | Vtama |
| Abbvie INC. | $25.05 | 2022 | |
| Mylan Specialty L.P. | $19.84 | 2023 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $19.81 | 2022 | |
| Leo Pharma INC. | $19.44 | 2025 | Anzupgo |
| Kedrion Biopharma, INC. | $16.72 | 2024 | Gammaked, Kedrab, Koate |
| Galderma Laboratories, L.P. | $15.56 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $15.39 | 2020 | |
| Covis Pharma Gmbh | $14.90 | 2023 | |
| Phadia US INC. | $13.26 | 2023 | Immunocap |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Dilley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.